Please assess the completion status of the following clinical trial:

Trial Title: Nebulized MgSO4 in Persistent Pulmonary Hypertension of Newborn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Newborns with PPHN fulfilling the following:~1. born at ≥ 37 weeks gestational age.~2. birth weight between 2.5 and 4 kg.~3. post-natal age between 6 and 72 hours.~4. connected to mechanical ventilation with an oxygenation index (OI) \> 30 on two occasions at least 15 minutes apart.~5. documented PPHN confirmed by echocardiography.~Exclusion Criteria:~1. failure to obtain informed consent.~2. infants of mothers who received magnesium sulfate within 48 hours before labor.~3. congenital heart diseases (other than PDA and foramen ovale).~4. major congenital anomalies (including congenital diaphragmatic hernia and lung hypoplasia).~5. prior need for cardiopulmonary resuscitation.~6. mean arterial blood pressure (MABP) \< 35 mmHg despite therapy with volume infusions and inotrpic support.~7. impaired kidney function.~8. prior administration of pulmonary vasodilators.

- Gender: ALL
- Minimum Age: 6 Hours
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- NebMag (Type: EXPERIMENTAL): Neonates with PPHN receiving nebulized magnesium sulfate and intravenous placebo
- IVMag (Type: ACTIVE_COMPARATOR): Neonates with PPHN receiving intravenous magnesium sulfate and nebulized placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).